CN115551549A - 用于通过靶向igsf8来治疗自身免疫疾病和癌症的组合物和方法 - Google Patents

用于通过靶向igsf8来治疗自身免疫疾病和癌症的组合物和方法 Download PDF

Info

Publication number
CN115551549A
CN115551549A CN202080097544.8A CN202080097544A CN115551549A CN 115551549 A CN115551549 A CN 115551549A CN 202080097544 A CN202080097544 A CN 202080097544A CN 115551549 A CN115551549 A CN 115551549A
Authority
CN
China
Prior art keywords
igsf8
antibody
cancer
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080097544.8A
Other languages
English (en)
Chinese (zh)
Inventor
X·刘
X·胡
T·肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gv20 Treatment Co ltd
Shanghai Xunbaihui Biotechnology Co ltd
Original Assignee
Gv20 Treatment Co ltd
Shanghai Xunbaihui Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gv20 Treatment Co ltd, Shanghai Xunbaihui Biotechnology Co ltd filed Critical Gv20 Treatment Co ltd
Publication of CN115551549A publication Critical patent/CN115551549A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080097544.8A 2019-12-25 2020-12-24 用于通过靶向igsf8来治疗自身免疫疾病和癌症的组合物和方法 Pending CN115551549A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/128294 2019-12-25
CN2019128294 2019-12-25
PCT/CN2020/139033 WO2021129744A1 (en) 2019-12-25 2020-12-24 Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8

Publications (1)

Publication Number Publication Date
CN115551549A true CN115551549A (zh) 2022-12-30

Family

ID=76575703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080097544.8A Pending CN115551549A (zh) 2019-12-25 2020-12-24 用于通过靶向igsf8来治疗自身免疫疾病和癌症的组合物和方法

Country Status (11)

Country Link
US (1) US20230056288A1 (https=)
EP (1) EP4081253A4 (https=)
JP (1) JP2023512151A (https=)
KR (1) KR20220151161A (https=)
CN (1) CN115551549A (https=)
AU (1) AU2020413633A1 (https=)
CA (1) CA3165908A1 (https=)
IL (1) IL294280A (https=)
MX (1) MX2022008061A (https=)
TW (1) TW202135861A (https=)
WO (1) WO2021129744A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116724051A (zh) * 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535853A (ja) * 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
WO2012021840A2 (en) * 2010-08-13 2012-02-16 Biovest International, Inc. Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies
US20120100162A1 (en) * 2006-09-15 2012-04-26 Accentia Biopharmaceuticals, Inc. Cyclophosphamide in Combination with Immune Therapeutics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2824112B1 (en) * 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
EP3688011A4 (en) * 2017-10-25 2021-11-24 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
US12545728B2 (en) * 2019-02-04 2026-02-10 Lonza Sales Ag Treatment of cancer metastasis by targeting exosome proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535853A (ja) * 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
US20120100162A1 (en) * 2006-09-15 2012-04-26 Accentia Biopharmaceuticals, Inc. Cyclophosphamide in Combination with Immune Therapeutics
WO2012021840A2 (en) * 2010-08-13 2012-02-16 Biovest International, Inc. Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KETTNER SANDRA 等: ""EWI-2/CD316 Is an Inducible Receptor of HSPA8 on Human Dendritic Cells"", MOLECULAR AND CELLULAR BIOLOGY, vol. 27, no. 21, 1 November 2007 (2007-11-01), pages 7718 *

Also Published As

Publication number Publication date
AU2020413633A1 (en) 2022-08-18
TW202135861A (zh) 2021-10-01
CA3165908A1 (en) 2021-07-01
JP2023512151A (ja) 2023-03-24
EP4081253A1 (en) 2022-11-02
KR20220151161A (ko) 2022-11-14
US20230056288A1 (en) 2023-02-23
EP4081253A4 (en) 2023-09-06
MX2022008061A (es) 2022-10-27
IL294280A (en) 2022-08-01
WO2021129744A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
EP3283527B1 (en) Combination therapy for cancer
JP2023088925A (ja) Ｐｓｇｌ－１アンタゴニスト及びその使用
JP7719799B2 (ja) 抗ガレクチン－９抗体およびその使用
JP7801225B2 (ja) 抗ｔｎｆｒ２抗体及びその使用
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
EP4367140A1 (en) Anti-tnfr2 antibody and uses thereof
CN115551549A (zh) 用于通过靶向igsf8来治疗自身免疫疾病和癌症的组合物和方法
US12617860B2 (en) Anti-TNFR2 antibody and uses thereof
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40092079A (zh) 抗tnfr2抗体和其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250605

Address after: 200120 Shanghai Pudong New Area Zhangjiang High-tech Park No. 3728 Jinke Road Building 4, 3rd Floor

Applicant after: Shanghai xunbaihui Biotechnology Co.,Ltd.

Country or region after: China

Applicant after: GV20 Treatment Co.,Ltd.

Country or region after: U.S.A.

Address before: 201203 Shanghai Pudong New Area, Cailun Road No. 81

Applicant before: SHANGHAI XUNBAIHUI BIOTECHNOLOGY CO.,LTD.

Country or region before: China

Applicant before: GV20 Treatment Co.,Ltd.

Country or region before: U.S.A.

TA01 Transfer of patent application right
CB02 Change of applicant information

Country or region after: China

Address after: 201203 Shanghai Pudong New Area, China (Shanghai) Pilot Free Trade Zone, Building 1, 4th Floor, Darwin Road 88

Applicant after: Shanghai xunbaihui Biotechnology Co.,Ltd.

Country or region after: U.S.A.

Applicant after: GV20 Treatment Co.,Ltd.

Address before: 200120 Shanghai Pudong New Area Zhangjiang High-tech Park No. 3728 Jinke Road Building 4, 3rd Floor

Applicant before: Shanghai xunbaihui Biotechnology Co.,Ltd.

Country or region before: China

Applicant before: GV20 Treatment Co.,Ltd.

Country or region before: U.S.A.

CB02 Change of applicant information